StockData
Humacyte, Inc. logo

Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$0.54−0.02 (-3.24%)

Close on Nov 16, 2026Market cap $150.09MP/E –Yield –

Humacyte gross margin

Gross margin is gross profit as a percentage of revenue.

Humacyte's gross margin for the twelve months ending Jun 30, 2026 was -494.6%. For fiscal 2025 it was -376.1%.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-376.1%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-203.2%−232.4
Q1 FY2026Mar 31, 2026-311.7%−383.3
Q4 FY2025Dec 31, 2025-1844.8%–
Q3 FY2025Sep 30, 202565.5%–
Q2 FY2025Jun 30, 202529.2%–
Q1 FY2025Mar 31, 202571.6%–

More Humacyte figures

See a number that looks wrong?